A study on the clinical characteristics including severity of pulmonary fibrosis by COVID-19
Not Applicable
- Conditions
- Certain infectious and parasitic diseases
- Registration Number
- KCT0006312
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients aged over 19 who admitted to ICU and needed mechanical ventilation due to COVID-19 infection
Patients who were confirmed pneumonia by radiological imaging
Patients with severe or critical status based on COVID-19 WHO clinical classification
Exclusion Criteria
Patients who were previously diagnosed with interstitial lung disease
Patients who had been intubated in other hospitals and refered to study hospital
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pulmonary fibrosis
- Secondary Outcome Measures
Name Time Method ot applicable
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link SARS-CoV-2 infection to pulmonary fibrosis progression in KCT0006312?
How do biomarkers like surfactant protein-D or KL-6 correlate with fibrosis severity in post-COVID patients in this trial?
What comparative outcomes exist between antifibrotic therapies (e.g., pirfenidone, nintedanib) and standard care for post-COVID pulmonary fibrosis?
Are TGF-β or IL-6 inhibitors being evaluated as potential treatments for fibrosis in KCT0006312 or related trials?
What adverse events are associated with long-term pulmonary fibrosis in post-COVID patients observed in this study?